ClinicalTrials.gov
public full text
Public Domain
Stiripentol in Dravet Syndrome
The patient has failed all other available agents and has intractable epilepsy due to Dravet Syndrome. Stiripentol is highly efficacious in Dravet Syndrome. The overall goals of therapy with Stiripentol are primarily to significantly reduce the frequency and severity of seizures.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Cardiac Arrhythmias in Dravet Syndrome#848298
- LEONIDaS Caregivers Study#839132
- Genetic Developmental and Epileptic Encephalopathy Natural History Study for Clinical Trial Readiness#839729
- Study to Evaluate the Safety and Effectiveness of USL255 in Patients With Refractory Partial-onset Seizures#833336
- Integrating rare and common variation in epilepsy genetics: from genetic architecture to penetrance and clinical expressivity.#666139
Record · ID 917187
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive